Population-level impact of infant 10-valent pneumococcal conjugate vaccination on adult pneumonia hospitalisations in Finland

Omar Okasha,¹ Hanna Rinta-Kokko,² Arto A Palmu,² Esa Ruokokoski,² Jukka Jokinen,² J Pekka Nuorti^{1,3}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2017-210440>).

¹Department of Epidemiology, Health Sciences, Faculty of Social Sciences, University of Tampere, Tampere, Finland

²Department of Public Health Solutions, National Institute for Health and Welfare (THL), Helsinki, Finland

³Department of Health Security, National Institute for Health and Welfare (THL), Helsinki, Finland

Correspondence to

Prof J Pekka Nuorti, Department of Epidemiology, Health Sciences, Faculty of Social Sciences, University of Tampere, Tampere 33100, Finland; Pekka.Nuorti@uta.fi

The main findings were presented in part at the 10th International Symposium on Pneumococci and Pneumococcal Diseases, Glasgow, Scotland, 26–30 June 2016.

Received 25 April 2017

Revised 18 August 2017

Accepted 18 September 2017

Published Online First

7 October 2017

ABSTRACT

Introduction Limited data are available on population-level herd effects of infant 10-valent pneumococcal conjugate vaccine (PCV10) programmes on pneumonia. We assessed national trends in pneumococcal and all-cause pneumonia hospitalisations in adults aged ≥ 18 years, before and after infant PCV10 introduction in 2010.

Methods Monthly hospitalisation rates of International Statistical Classification of Diseases, 10th revision (ICD-10)-coded primary discharge diagnoses compatible with pneumonia from 2004–2005 to 2014–2015 were calculated with population denominators from the population register. Trends in pneumonia before and after PCV10 introduction were assessed with interrupted time-series analysis. Rates during the PCV10 period were estimated from adjusted negative binomial regression model and compared with those projected as continuation of the pre-PCV10 trend. All-cause hospitalisations were assessed for control purposes.

Results Before PCV10, the all-cause pneumonia rate in adults aged ≥ 18 years increased annually by 2.4%, followed by a 4.7% annual decline during the PCV10 period. In 2014–2015, the overall all-cause pneumonia hospitalisation rate was 109.3/100 000 (95% CI 96.5 to 121.9) or 15.4% lower than the expected rate. A significant 6.7% decline was seen in persons aged ≥ 65 years (131.5/100 000), which translates to 1456 fewer pneumonia hospitalisations annually. In comparison, hospitalisations other than pneumonia decreased by 3.5% annually throughout the entire study period.

Conclusion These national data suggest that herd protection from infant PCV10 programme has reversed the increasing trend and substantially decreased all-cause pneumonia hospitalisations in adults, particularly the elderly.

INTRODUCTION

Lower respiratory infections are the fourth common cause of death globally.¹ Community-acquired pneumonia (CAP) causes significant clinical and economic burden associated with hospitalisations, particularly in the elderly.² Recent estimates of the proportion of CAP that is attributable to *Streptococcus pneumoniae* (pneumococcus) in adults have ranged from 19% to 27%. However, because sensitive and specific assays are not routinely used in clinical practice—particularly for non-hospitalised cases—these estimates may

Key messages

What is the key question?

► In a nationwide, population-based study, we assessed whether vaccinating infants with the 10-valent pneumococcal conjugate vaccine (PCV10) had had an impact on adult pneumonia hospitalisations through herd protection.

What is the bottom line?

► Although there was an increasing trend in rates of pneumonia before PCV10, five years after infant PCV10 introduction, all-cause pneumonia hospitalisations had decreased significantly in all adult age groups, particularly the elderly.

Why read on?

► In high-income countries, the ageing of population and the uncertain cost-effectiveness of preventing adult pneumococcal disease by direct vaccination highlight the public health significance of the pneumococcal conjugate vaccine programme's indirect impact in reducing the burden of adult pneumonia.

be conservative.^{3 4} In a recent prospective cohort study of Finnish adults ≥ 65 years of age, CAP incidence was estimated to be 1050 cases/100 000 person-years; 17% of cases were due to *S. pneumoniae*, and 85% required hospitalisation.⁵ In the USA, the annual incidence of hospitalised CAP in adults ≥ 80 years of age was estimated to be >1600 cases/100 000.⁶

Prelicensure clinical trials suggested a 20%–40% effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) against radiologically confirmed pneumonia in children ≤ 5 years of age.^{7 8} In persons ≥ 65 years of age, one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) reduced vaccine-serotype CAP by 45% in the Netherlands but had little impact on overall pneumonia.⁹ After introduction of PCV7—and subsequently PCV13—in routine infant immunisation programmes, several population-based studies reported reductions in all-cause pneumonia hospitalisations in children.^{10 11} In Finland, 10-valent pneumococcal conjugate vaccine (PCV10) introduction was recently shown to have substantially

► <http://dx.doi.org/10.1136/thoraxjnl-2017-210440>

Check for updates

To cite: Okasha O, Rinta-Kokko H, Palmu AA, et al. *Thorax* 2018;**73**:262–269.

decreased the incidence of pneumonia in both vaccine-eligible and older, unvaccinated children.¹² Infant pneumococcal conjugate vaccines (PCVs) decrease carriage of vaccine-serotype pneumococci and, consequently, transmission to unvaccinated groups.¹³ Few studies, however, have evaluated the population-level herd effects of infant PCVs on adult pneumonia hospitalisations.^{14–17} Given the increasing burden of pneumonia hospitalisations associated with ageing of the population, reducing morbidity and mortality from pneumonia in adults by infant pneumococcal vaccination would yield major public health benefits.¹⁸

We conducted a nationwide register linkage study to assess the public health impact of infant PCV10 programme introduction on all-cause and pneumococcal pneumonia hospitalisations in adults ≥ 18 years of age in Finland.

METHODS

Pneumococcal vaccination in Finland

In September 2010, PCV10 was introduced in the Finnish National Vaccination Programme (NVP) under a three-dose schedule (at 2, 5 and 12 months of age) without catch-up programme. All children born after June 2010 were eligible. In the 2012 birth cohort, the uptake of at least one dose of PCV10 was estimated to be 94%.¹⁹ Use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and PCV13 in adults at risk and the elderly is recommended. However, there is no national adult vaccination programme, and in 2014 the cumulative coverage of both vaccines in adults was $<5\%$ on the basis of vaccine distribution data.

Study population and data sources

This was a nationwide, population-based, quasiexperimental study. The national hospital discharge register includes discharge notifications for inpatient admissions and outpatient visits from all Finnish hospitals. International Statistical Classification of Diseases, 10th revision (ICD-10)-coded discharge diagnoses and visit dates for pneumonia hospitalisations in all adults ≥ 18 years of age from 2004–2005 to 2014–2015 (epidemiological years from July to June) were extracted; population denominators were from the population information system. Data were analysed in the following age groups: 18–49, 50–64, ≥ 65 and ≥ 18 years of age. The age group ≥ 65 years was further divided into 65–74, 75–84 and ≥ 85 years of age.

Pneumonia definitions

All-cause pneumonia hospitalisation was defined as record of a patient hospitalised for at least overnight with ICD-10-coded pneumonia as the primary discharge diagnosis (J10–J18 and J86; online supplementary tables 1 and 2). Pneumococcal pneumonia and empyema were defined as patients with ICD-codes J13 and J86, respectively, in any discharge diagnosis field, with or without overnight hospitalisation. Potential multiple pneumonia discharge records for the same patient within 90 days from the date of the index pneumonia diagnosis were combined into one episode. The hospital discharge dataset included no radiological data. All-cause hospitalisations, defined as records of patients hospitalised for at least overnight with ICD-10 discharge codes other than J10–J18 and J86, were assessed for comparison.

Statistical analysis

Interrupted time-series analysis was used to compare rates of adult pneumonia before and after infant PCV10 introduction. The comparison periods for analysis included the pre-PCV10 period (epidemiological years from 2004–2005 to 2009–2010;

ie, 72 monthly data points) and the PCV10 period (epidemiological years from 2011–2012 to 2014–2015; ie, 48 monthly data points); 2010–2011 was considered a transitional period and excluded from the analysis.

Separate models were fitted for each case definition (all-cause pneumonia, pneumococcal pneumonia, empyema and all-cause hospitalisations), age group and for the whole adult population. In all models, the outcome was the monthly number of episodes with the log of the population/100 000 as offset,²⁰ and the reported measure was monthly incidence rate ratio (IRR), which was exponentiated to estimate the annual IRR. The model parameters included the baseline rate at the beginning of the study and the trend before and after PCV10 introduction. Our model did not include the change in level as an immediate effect after the intervention because this is more relevant for studying the direct effect of PCVs on pneumonia hospitalisations in vaccine-eligible children.¹¹ In contrast, PCV-attributed herd protection in adults appears to have a ‘lag period’ before coming into full effect²¹ and in the absence of a clear definition of such lag period, setting the time point for the change in level a priori would have been largely subjective. All models were adjusted for sex, and models for the aggregate age groups were age adjusted. To account for seasonal fluctuation in rates, all models included a Fourier seasonality component with the linear combinations of sine and cosine functions:

$$\log E(Y_t) = \log(C_t) + \beta_0 + \beta_1 T_t + \beta_2 X_t T_t + \beta_3 \sin[2\pi/12] + \beta_4 \cos[2\pi/12] + \beta_5 G_t$$

where Y_t is the number of pneumonia episodes measured at month t . $\log(C_t)$ is the offset equal to the log of the population C_t divided by 100 000. β_0 is baseline rate. T_t is the time since the beginning of the study until month t , and β_1 is the pre-PCV10 slope. $X_t T_t$ is an interaction term and β_2 represents the post-PCV10 trend. The sine and cosine terms represent the Fourier seasonality component. G_t is a binary representing sex.

Trends in pneumonia episodes before and after PCV10 were compared by estimating annual IRRs per 100 000 with the corresponding 95% CI. The IRR of the trend before PCV10 is estimated as the change in annual hospitalisation rates from the first year in the observation period. The IRR of the trend after PCV10 is estimated as the comparison of the annual trend in hospitalisation rate following the start of the PCV10 period to the period before. Percentage annual changes in trend were calculated as $(IRR - 1) \times 100$.

To quantify the indirect impact of PCV10, the rate at the end of the study period (ie, epidemiological year 2014–2015) was estimated as the non-linear prediction from the model with the full set of parameters and was then compared with the expected rate that would have occurred in the absence of PCV10 introduction. The expected rates were non-linearly predicted as continuation of the trend in the period before PCV10, by holding the model parameter denoting the trend after PCV10 at zero.²² The number of prevented pneumonia admissions per year was estimated by multiplying the annual absolute rate reduction by the population size in 2014–2015. To smoothen the seasonal variation in the graphical presentation, symmetrical 12-month moving average filters were applied to average monthly estimated and expected rates. Incidence rate residual analysis was done, including tests for autocorrelation and partial autocorrelations. These indicated no significant deviances from model assumptions. The level of statistically significant two-tailed p value was <0.05 . Stata/SE V.14 was used in statistical analyses. The study protocol was

Table 1 Hospitalisations for pneumonia episodes in adults ≥ 18 years of age, Finland, epidemiological years from 2004–2005 to 2014–2015

Epidemiological years*	Total population ≥ 18 years of age	Pneumonia episodes†					
		All-cause pneumonia hospitalisations		Empyema		Pneumococcal pneumonia	
		n	Rate per 100 000 population	n	Rate per 100 000 population	n	Rate per 100 000 population
2004–2005	4 141 374	20 823	502.8	198	4.8	377	9.1
2005–2006	4 164 582	20 542	493.3	179	4.3	338	8.1
2006–2007	4 190 862	20 821	496.8	197	4.7	402	9.6
2007–2008	4 219 620	21 082	499.6	237	5.6	395	9.4
2008–2009	4 248 882	23 640	556.4	264	6.2	516	12.1
2009–2010	4 276 986	22 394	523.6	264	6.2	449	10.5
2010–2011	4 305 246	26 744	621.2	273	6.3	437	10.2
2011–2012	4 333 734	28 609	660.2	294	6.8	441	10.2
2012–2013	4 361 280	26 376	604.8	291	6.7	469	10.8
2013–2014	4 385 442	25 189	574.4	309	7.0	447	10.2
2014–2015	4 405 260	27 162	616.6	307	7.0	407	9.2
Total	–	263 382	–	2813	–	4678	–

*Years runs from July to June.

†Potential multiple pneumonia discharge records for the same patient within 90 days from the date of the index pneumonia diagnosis were combined into one episode.

approved by the institutional review board in the National Institute for Health and Welfare (THL), Finland. Permissions to use the register data for research were obtained from the register controller at THL.

RESULTS

Characteristics of pneumonia hospitalisations

During the study period (2004–2004 to 2014–2015), >21.7 million hospital discharges were recorded in Finnish adults ≥ 18 years of age; 263 382 (1.2%) were all-cause pneumonia hospitalisation episodes. Pneumococcal pneumonia and empyema accounted for 1.8% and 1.1% of pneumonia episodes, respectively (table 1). The baseline rate of and number of all-cause pneumonia hospitalisations in 2004–2005 were 502.8/100 000 and 20 823, respectively (table 2). The baseline rates ranged from 167.9/100 000 in persons 18–49 years of age to 4434.3/100 000 in those ≥ 85 years of age. The overall baseline rates for pneumococcal pneumonia and empyema were low (9.1 and 4.8/100 000, respectively).

Trends in pneumonia rates during the pre-PCV10 period

From July 2004 to June 2010, the rates of all-cause pneumonia hospitalisations in adults ≥ 18 years of age increased by 2.4% annually (IRR 1.024; 95% CI 1.018 to 1.037) (table 2). Similarly, rates of both pneumococcal pneumonia and empyema increased annually by 3.7% and 6.2% (IRRs 1.037 and 1.062, respectively). Age-stratified trend analysis showed increases in rates of all-cause pneumonia hospitalisations during the pre-PCV10 period in all age groups (table 2).

Trends in pneumonia rates during the PCV10 period

From July 2011 to June 2015, the all-cause pneumonia rates in adults ≥ 18 years of age decreased annually by 4.7% (IRR 0.953; 95% CI 0.942 to 0.965) (table 2). Statistically significant declines were seen in all age-specific rates except for adults ≥ 75 years of age; the largest reduction was seen in age groups 18–49 and 50–64 years (9.2%). The rate of pneumococcal pneumonia decreased annually by 8.1% (IRR 0.919; 95% CI 0.876 to 0.965); significant annual declines of 14.5% were seen in adults <65

years of age. Reductions in empyema rates were non-significant (table 2).

Potential outcomes analysis

In epidemiological year 2014–2015, the estimated annual rate of all-cause pneumonia hospitalisations in adults ≥ 18 years of age was 109.3 episodes/100 000 (95% CI 96.5 to 121.9) or 15.4% lower compared with the expected rate on the basis of pre-PCV10 trends (table 3, figure 1). For pneumococcal pneumonia, the overall rate reduction in 2014 was estimated to be 3.5 episodes per 100 000 (95% CI 2.5 to 4.4) or 26.5%. By 2014–2015, the overall reduction in empyema was 1.5 episodes/100 000 (95% CI 0.9 to 2.1) (table 3).

In age-stratified analyses, statistically significant reductions in all-cause pneumonia hospitalisations were seen in all age groups (table 3, figure 2). Compared with the expected rate, the estimated reductions in all-cause pneumonia hospitalisations in age groups 18–49, 50–64 and ≥ 65 years were 44.1 (26.9%), 140.6 (28.8%) and 131.5 (6.7%) per 100 000 person-years, respectively. The greatest absolute reduction was seen in persons ≥ 85 years (195.9/100 000). During 2014–2015, there were a total of 20 506 pneumonia hospitalisations among the 1 107 240 persons ≥ 65 years of age; the estimated rate decrease translates to 1456 fewer pneumonia hospitalisations in this age group. Likewise, the estimated rate decreases in age groups 18–49 years (population: 2 180 022) and 50–64 years (population: 1 117 998) translate to 961 and 1572 fewer pneumonia hospitalisations in 2014–2015, respectively. Persons <65 years of age had an estimated 41% reduction in pneumococcal pneumonia. Similar per cent reduction was seen in persons ≥ 85 years of age, with the greatest absolute reduction in pneumococcal pneumonia rates (13.0 episodes/100 000). In persons 75–84 years of age, however, the estimated rates were higher than expected by 5.4 episodes/100 000. By the end of the study period, the overall and age-stratified rates of empyema were significantly lower than expected, except for the youngest and the oldest age groups (table 3).

Control condition: trends in all-cause hospitalisations

Before PCV10 introduction, all-cause hospitalisations (excluding pneumonia) decreased annually by 3.5% (IRR 0.965; 95% CI

Table 2 Trends in hospitalisations for all-cause pneumonia, pneumococcal pneumonia and empyema in adults ≥ 18 years of age before and after introduction of 10-valent pneumococcal conjugate vaccine (PCV10) in the national infant vaccination programme, Finland

Outcome		Baseline rate in 2004–2005 (per 100 000 population)	Adjusted annual trends using interrupted time-series analysis					
			Period before PCV10 (from 2004–2005 to 2009–2010*)			Period after PCV10 (from 2011–2012 to 2014–2015*)		
			Annual trend			Annual trend		
			IRR	95% CI	p†	IRR	95% CI	p†
All-cause pneumonia								
Age (years)								
18–49	167.9	1.012	0.988 to 1.037	0.075	0.908	0.876 to 0.953	<0.001	
50–64	310.6	1.049	1.037 to 1.062	<0.001	0.908	0.876 to 0.930	<0.001	
≥65‡	1639.8	1.018	1.013 to 1.023	<0.001	0.976	0.965 to 0.988	0.004	
65–74	816.7	1.024	1.012 to 1.037	<0.001	0.965	0.942 to 0.988	0.016	
75–84	2071.8	1.012	1.007 to 1.024	<0.001	0.976	0.965 to 1.002	0.081	
≥85	4434.3	1.024	1.012 to 1.028	<0.001	0.988	0.965 to 1.012	0.375	
Total‡	502.8	1.024	1.018 to 1.037	<0.001	0.953	0.942 to 0.965	<0.001	
Pneumococcal pneumonia								
Age (years)								
18–49	5.7	1.037	1.002 to 1.087	0.029	0.855	0.775 to 0.953	0.003	
50–64	10.4	1.062	1.024 to 1.087	0.001	0.855	0.785 to 0.930	<0.001	
≥65‡	16.3	1.012	0.988 to 1.049	0.290	0.988	0.919 to 1.062	0.845	
65–74	11.3	1.037	0.988 to 1.087	0.073	0.976	0.876 to 1.074	0.604	
75–84	20.9	0.988	0.942 to 1.037	0.515	1.087	0.965 to 1.224	0.186	
≥85	25.6	1.024	0.953 to 1.087	0.590	0.865	0.711 to 1.037	0.105	
Total‡	9.1	1.037	1.012 to 1.049	<0.001	0.919	0.876 to 0.965	<0.001	
Empyema								
Age (years)								
18–49	2.4	1.024	0.976 to 1.062	0.378	0.976	0.865 to 1.114	0.736	
50–64	7.4	1.049	1.012 to 1.087	0.015	0.930	0.844 to 1.024	0.117	
≥65‡	7.7	1.100	1.062 to 1.154	<0.001	0.919	0.844 to 1.012	0.074	
65–74	8.9	1.100	1.037 to 1.154	<0.001	0.930	0.824 to 1.049	0.248	
75–84	4.7	1.114	1.049 to 1.196	0.001	0.908	0.766 to 1.074	0.266	
≥85	11.7	1.114	1.012 to 1.253	0.035	0.908	0.702 to 1.168	0.435	
Total‡	4.8	1.062	1.037 to 1.087	<0.001	0.942	0.897 to 1.002	0.059	

IRRs are adjusted for sex and seasonality, with the natural log of the population size as the offset variable. The IRR of the trend before PCV10 is estimated as the change in annual hospitalisation rates in the years 2004–2005 to 2009–2010. The IRR of the trend after PCV10 is estimated as the comparison of the annual trend in the years 2011–2012 to 2013–2014 to the trend in the period before.

*PCV10 was introduced in the Finnish NVP in September 2010. The year 2010–2011 was defined as a transitional period and was excluded from the analysis.

†Two-tailed p Value.

‡Analyses for the aggregate age groups (ie, the total (≥ 18 years of age) and the ≥ 65 years of age) were age adjusted using the following age groups: all age groups in the analyses for the total and the 65–74, 75–84 and ≥ 85 years of age in the analyses for the ≥ 65 years of age group.

IRR, incidence rate ratio; NVP, National Vaccination Programme.

0.953 to 0.976). The trend continued during the PCV10 period (online supplementary figure 1).

DISCUSSION

This study provides evidence of herd effects and population-level impact of an infant PCV10 programme on adult pneumonia hospitalisations in a high vaccine uptake setting. The analysis of trends and potential outcomes showed an increasing prevaccine trend in adult pneumonia hospitalisations, followed by significant declines in overall and age-stratified rates after PCV10 introduction. By 2014–2015, the rate of all-cause pneumonia hospitalisations in adults had declined by 15% or 109 episodes per 100 000 population. Our data highlight both the substantial

burden and opportunities for prevention of pneumonia in the elderly: reductions in all-cause pneumonia hospitalisations in persons ≥ 65 years of age indicated about 1500 fewer annual hospitalisations.

During the period before PCV10, rates of pneumonia admissions in adults ≥ 18 years of age increased by 2.4% annually. Greater rate increases were seen in hospitalisations in which the presumptive aetiology was reported, as the overall rates of pneumococcal pneumonia and empyema increased by 3.7% and 6% annually. Increasing trends in adult pneumonia admissions were seen in England during 1997–2005, in Denmark during 1994–2004, and in the USA during 1988–2002 (ie, mostly before introduction of infant PCV7 programmes in these

Table 3 Estimated and expected hospitalisation rates of all-cause pneumonia in adults ≥ 18 years of age, 2014–2015

			Expected versus estimated hospitalisation rates in 2014–2015		
Outcome	Estimated rate per 100 000 population*	Expected rate per 100 000 population†	Rate difference per 100 000 population	95% CI‡ per 100 000 population	Per cent reduction (%)
All-cause pneumonia					
Age (years)					
18–49	120.1	164.2	44.1	35.3 to 52.9	26.9
50–64	348.8	488.8	140.6	122.1 to 158.9.0	28.8
≥65§	1820.4	1951.9	131.5	106.0 to 156.9	6.7
65–74	869.3	968.4	99.1	73.1 to 125.0	10.2
75–84	2260.5	2417.3	156.8	106.7 to 206.9	6.5
≥85	5097.5	5293.3	195.9	77.3 to 314.4	3.7
Total§	598.8	708.0	109.3	96.5 to 121.9	15.4
Pneumococcal pneumonia					
Age (years)					
18–49	4.6	7.9	3.3	1.9 to 4.6	41.7
50–64	10.0	17.1	7.1	4.7 to 9.5	41.4
≥65§	18.9	19.4	0.5	–0.9 to 1.9	2.5
65–74	17.4	19.1	1.7	–0.7 to 4.2	9.1
75–84	21.7	16.3	–5.4	–5.9 to –4.8	–33.0
≥85	18.9	31.9	13.0	3.4 to 22.6	40.6
Total§	9.5	12.9	3.5	2.5 to 4.4	26.5
Empyema					
Age (years)					
18–49	2.8	3.0	0.2	–0.1 to 0.6	7.0
50–64	8.5	11.1	2.6	1.2 to 4.0	23.4
≥65§	13.8	18.4	4.6	1.9 to 7.2	24.9
65–74	13.4	17.3	3.8	0.5 to 7.1	22.2
75–84	13.8	19.1	5.3	0.2 to 10.4	27.8
≥85	15.9	22.5	6.6	–3.3 to 16.4	29.2
Total§	7.0	8.5	1.5	0.9 to 2.1	17.5

*Estimated rate is the average hospitalisation rate estimated from the adjusted negative binomial regression model, which included as independent variables the time since the beginning of the study and time since the start of the intervention period. The year 2010–2011 was considered a transitional period and excluded from the analysis.

†Expected rate is the average hospitalisation rate estimated from the adjusted model with the time since the beginning of the study as the independent variable.

‡95% CIs are estimated using Delta method and were considered significant if they did not include zero.

§Analyses for the aggregate age groups (ie, the total (≥ 18 years of age) and the ≥ 65 years of age) were age adjusted using the following age groups: all age groups in the analyses for the total, and the 65–74, 75–84 and ≥ 85 years of age in the analyses for the ≥ 65 years of age group.

countries).^{23–25} The long-term increasing trend in pneumonia hospitalisations may be associated with ageing of the population and increase in the prevalence of underlying medical conditions, both recognised risk factors for CAP.²⁶ The proportion of elderly hospitalised pneumonia patients who had underlying medical conditions increased in the USA during 1988–2002.²⁵ In the UK, however, an increase in pneumonia admissions in the elderly during 1998–2010 was independent of increases in comorbidities and was postulated to be associated with changes in service provision and health-seeking behaviour.²⁷ From 1996 to 2009, the number of pneumonia hospitalisations in Finland increased by 42%, primarily in the elderly; the duration of hospital stay, however, decreased.²⁸ Changes in coding practices may also be associated with increases in pneumonia hospitalisations, but this is unlikely to have influenced our findings because we used only the primary discharge diagnosis and included all pneumonia-related ICD-10 codes in the analysis. We conducted an additional analysis of all episodes in which ICD-10-coded pneumonia was listed in any position of the discharge diagnoses, with or without

hospitalisation. The relative reductions in pneumonia were similar to the analysis in which the case definition was restricted to the primary discharge diagnosis, but the absolute reductions were larger (online supplementary tables 1 and 2).

Our trend analysis showed significant declines in rates of all-cause pneumonia hospitalisations following PCV10 introduction. In persons ≥ 65 years of age, the estimated annual decline was 2.4%, and in those 18–49 and 50–64 years of age, it was 9.2%. In younger adults, rates of pneumococcal pneumonia also decreased. The large burden of all-cause pneumonia hospitalisations in persons ≥ 85 years of age, however, was associated with the greatest absolute reduction, an estimated 195.9 fewer episodes per 100 000 than expected, that is, had the increasing pre-PCV10 trend continued. Population-based prospective surveillance studies have consistently reported that rates of CAP hospitalisations increase with advancing age.^{2,5} In Finland, pneumonia hospitalisations were previously projected to increase by 49% from 2010 to 2030.²⁸ Percentage reductions in all-cause pneumonia hospitalisations, however, were greatest in young

Figure 1 The vertical black dash-dot line marks to the introduction of PCV10 in the Finnish National Vaccination Programme. The period between the vertical red dash lines, that is, July 2010–June 2011, is a transitional period and was excluded from the analysis. Observed rate is the unadjusted average monthly hospitalisation rate. Estimated rate is the average hospitalisation rate estimated from the adjusted negative binomial regression model with the full set of parameters (ie, time since the beginning of the study and time since the start of the intervention period). Expected rate is the average rate estimated from the model with time since the beginning of the study as the only independent variable. Twelve-month moving average filter was applied to both estimated and expected rates. PCV10, 10-valent pneumococcal conjugate vaccine.

adults (26.9% in adults 18–49 years of age), which might be associated with reduced exposure to PCV10 serotypes in parents of vaccinated children. Although previous studies evaluating the impact of infant PCV7 programmes on adult pneumonia hospitalisations have consistently showed declines in pneumococcal pneumonia, the reported changes in age-specific all-cause pneumonia hospitalisation rates have varied across settings.^{15–17} This variation could be associated with several factors or their combination, including differences in infant vaccination programmes (eg, uptake, schedule or catch-up), population characteristics, coding practices, admission criteria or analytical methods.

Some limitations should be considered when interpreting the findings. First, the study design was ecological. Although our study aimed to estimate the indirect effect of infant PCV10, other adult vaccines, such as influenza, PCV13 and the PPSV23, may also decrease the risk of pneumonia hospitalisation. In Finland, influenza vaccination has been recommended for all persons ≥ 65 years of age since 2002. During our study period, the annual vaccine coverage varied from 38% to 50%. Uptake was highest during the 2009 influenza pandemic but actually decreased in subsequent years, that is, during PCV10 period. In 2014, the cumulative coverage of PPSV23 and PCV13 in adults was $< 5\%$ based on vaccine distribution data. This low coverage would not be expected to have a population-level impact on overall pneumonia incidence.

Second, all-cause pneumonia is a non-specific outcome, and trends in other respiratory pathogens may influence its occurrence. In 2010–2011, an increase in all-cause pneumonia was observed. Although this coincided with an epidemic of *Mycoplasma pneumoniae* infections in Finland, it is unlikely to have

influenced our findings as most cases were in younger age groups (5–19 years of age), and the period (late-2010 to mid-2011) was excluded from our analysis.²⁹ In our study, some 95% of episodes were recorded as pneumonia due to unspecified cause, indicating the lack of sensitive and specific aetiological diagnosis for pneumonia in a routine hospital care.^{3–4} To capture all episodes of pneumococcal pneumonia and empyema, we used broader case definition (with or without overnight hospitalisations) and also included non-primary discharge diagnoses. Nevertheless, these outcomes accounted only for $< 2\%$ of pneumonia episodes in our study. In previous reports, laboratory-confirmed pneumococcal pneumonia accounted for a small fraction of all-cause pneumonia hospitalisations.^{15–17} In addition, our sensitivity analysis showed no significant changes in pneumonia hospitalisations due to specified pathogens other than *S. pneumoniae* (data not shown). Our case definition also included healthcare-associated pneumonia, which is difficult to distinguish from CAP in hospital discharge records and is mainly caused by bacteria other than *S. pneumoniae*.

Third, administrative data are subject to misclassification, secular changes in coding and clinical practices, as well as criteria for admission.³⁰ However, an Australian validation study estimated 98% sensitivity, 97% specificity, 96% positive predictive value and 98% negative predictive value for ICD-10-coded pneumonia hospitalisations.³¹ In the USA, comparison of IPD rates reported by active surveillance with those estimated using ICD-coded data showed similar temporal trends.¹⁰ Changes in admission criteria might be associated with the observed changes in pneumonia hospitalisation rates, particularly if there was a shift to management of less severe cases in outpatient settings.³²

Figure 2 The vertical black dash-dot line marks to the introduction of PCV10 in the Finnish National Vaccination Programme. The period between the vertical red dash lines, that is, July 2010–June 2011, is a transitional period and was excluded from the analysis. Observed rate is the unadjusted average monthly hospitalisation rate. Estimated rate is the average hospitalisation rate estimated from the adjusted negative binomial regression model with the full set of parameters (ie, time since the beginning of the study and time since the start of the intervention period). Expected rate is the average rate estimated from the model with time since the beginning of the study as the only independent variable. Twelve-month moving average filter was applied to both estimated and expected rates. PCV10, 10-valent pneumococcal conjugate vaccine.

The Finnish guidelines for the management of CAP published in 2008 introduced criteria for identifying low-risk patients who could be managed on outpatient basis.³³ We therefore conducted a sensitivity analysis that showed that pneumonia hospitalisations continued to increase after the guidelines were published and began to decrease only during the PCV10 period (online supplementary figure 2). However, trends in outpatient visits for CAP could not be examined, as the outpatient register was established only after PCV10 introduction. The results of an additional analysis, which also included outpatient and emergency room pneumonia episodes, were similar to the analysis restricted to hospitalised episodes (online supplementary tables 1 and 2). It is possible that the decreasing trend in hospitalisations other than pneumonia might be associated with a shift towards outpatient management of various conditions, but this is unlikely to have influenced the observed trends in all-cause pneumonia hospitalisations.

Last, increases in chronic medical conditions that increase the risk of pneumococcal pneumonia also contribute to the disease burden. We could not assess the potential effect of underlying conditions in this study due to the complexity of obtaining comprehensive data on these conditions. Assessing whether indirect vaccine effects against pneumonia are different in persons

with and without comorbidities will help better defining the characteristics of herd protection in adults.

The strengths of this study included the use of comprehensive, nationwide, population-based register data with a case definition for pneumonia hospitalisation with increased specificity of the main outcome, hospital-treated primary pneumonia. Although our dataset did not include radiological data, it is likely that our case definition captured most radiologically confirmed episodes as patients were hospitalised at least overnight, and pneumonia was the primary discharge diagnosis. Our data enabled using interrupted time-series analysis with sufficient data points before and after infant PCV10 to estimate the herd effect on adult pneumonia hospitalisations. This analysis method had advantages over the two-point, before–after design because it incorporated multiple time points and enabled accounting for seasonal variation and, importantly, the prevaccine secular increase in pneumonia hospitalisations in Finland.²⁸ Last, our analysis showed the trends in all-cause hospitalisations or potential shifts in outpatient management of CAP were unlikely to explain the trends in pneumonia hospitalisations.

In conclusion, these national data suggest that herd protection from infant PCV10 has reversed the increasing trend and

substantially decreased all-cause pneumonia hospitalisations in adults, particularly in the elderly. This finding is significant as the number of persons ≥ 65 years of age in Finland is projected to increase by 17% from 2014 to 2020, likely increasing the burden of CAP hospitalisations even further.³⁴ The findings also have major implications for economic analyses comparing strategies for prevention of pneumococcal diseases in adults.

Acknowledgements We would like to thank Dr Hanna Nohynek for her comments on an earlier version of this manuscript. OO was supported by the International Doctoral Programme in Epidemiology, Health Sciences, Faculty of Social Sciences, University of Tampere, Finland.

Contributors Study concept and design: OO, AAP, JJ and JPN. Acquisition of data: HR-K and ER. Analysis and interpretation of data: OO, HR-K, AAP, JJ and JPN. Drafting of the manuscript: OO and JPN. Critical revision of the manuscript for important intellectual content: OO, HR-K, AAP, JJ and JPN. Statistical analysis: OO and HR-K. Obtained funding: JPN. Study supervision: JPN. Final approval: OO, HR-K, AAP, ER, JJ and JPN.

Funding The study was funded by The National Institute for Health and Welfare (THL), and Health Sciences, Faculty of Social Sciences, University of Tampere, Finland. The study was partially supported by the Integrated Monitoring of Vaccine in Europe (I-MOVE+) project, which has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no. 634446.

Competing interests OO and JPN: no conflict of interest. HR-K, ER, AAP, and JJ are employees of the National Institute for Health and Welfare, Department of Public Health Solutions, which has received research funding from GlaxoSmithKline for a nationwide effectiveness trial of the 10-valent pneumococcal conjugate vaccine. HR-K, AAP, ER, and JJ are coinvestigators in the trial.

Ethics approval National Institute for Health and Welfare (THL), Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Wang H, Naghavi M, Allen C, *et al.* Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1459–544.
- Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. *Thorax* 2012;67:71–9.
- Said MA, Johnson HL, Nonyane BA, *et al.* Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. *PLoS One* 2013;8:e60273.
- Rozenbaum MH, Pechlivanoglou P, van der Werf TS, *et al.* The role of Streptococcus pneumoniae in community-acquired pneumonia among adults in Europe: a meta-analysis. *Eur J Clin Microbiol Infect Dis* 2013;32:305–16.
- Palma AA, Saukkoriipi A, Snellman M, *et al.* Incidence and etiology of community-acquired pneumonia in the elderly in a prospective population-based study. *Scand J Infect Dis* 2014;46:250–9.
- Jain S, Self WH, Wunderink RG, *et al.* Community-acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med* 2015;373:415–27.
- Black SB, Shinefield HR, Ling S, *et al.* Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. *Pediatr Infect Dis J* 2002;21:810–5.
- Cutts FT, Zaman SM, Enwere G, *et al.* Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. *Lancet* 2005;365:1139–46.
- Bonten MJ, Huijts SM, Bolkenbaas M, *et al.* Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med* 2015;372:1114–25.
- Simonsen L, Taylor RJ, Young-Xu Y, *et al.* Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. *MBio* 2011;2:e00309–10.
- Saxena S, Atchison C, Cecil E, *et al.* Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England. *J Infect* 2015;71:428–36.
- Palma AA, Rinta-Kokko H, Nohynek H, *et al.* Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. *PLoS One* 2017;12:e0172690.
- van Hoek AJ, Sheppard CL, Andrews NJ, *et al.* Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. *Vaccine* 2014;32:4349–55.
- Grijalva CG, Nuorti JP, Arbogast PG, *et al.* Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. *Lancet* 2007;369:1179–86.
- Griffin MR, Zhu Y, Moore MR, *et al.* U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. *N Engl J Med* 2013;369:155–63.
- Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. *Pediatr Infect Dis J* 2010;29:607–12.
- Menzies RI, Jardine A, McIntyre PB. Pneumonia in elderly australians: reduction in presumptive pneumococcal hospitalizations but No change in all-Cause pneumonia hospitalizations following 7-valent pneumococcal conjugate vaccination. *Clin Infect Dis* 2015;61:927–33.
- Nuorti P, Reingold A. Preventing pneumococcal infections in older adults. *Lancet Respir Med* 2015;3:834–6.
- National Institute for Health and Welfare (THL). Rokotusrekisteri (The Vaccination Register). <https://www.thl.fi/fi/web/rokottaminen/rokotusohjelma/rokotusrekisteri> (accessed 22 Jun 2017).
- Hilbe J. *Negative Binomial Regression*. 2nd edn. Cambridge: Cambridge University Press, 2011.
- Feikin DR, Kagucia EW, Loo JD, *et al.* Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. *PLoS Med* 2013;10:e1001517.
- Wagner AK, Soumerai SB, Zhang F, *et al.* Segmented regression analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther* 2002;27:299–309.
- Trotter CL, Stuart JM, George R, *et al.* Increasing hospital admissions for pneumonia, England. *Emerg Infect Dis* 2008;14:727–33.
- Thomsen RW, Riis A, Nørgaard M, *et al.* Rising incidence and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Denmark. *J Intern Med* 2006;259:410–7.
- Fry AM, Shay DK, Holman RC, *et al.* Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988–2002. *JAMA* 2005;294:2712–9.
- Torres A, Peetermans WE, Viegi G, *et al.* Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax* 2013;68:1057–65.
- Millett ER, De Stavola BL, Quint JK, *et al.* Risk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort study. *BMJ Open* 2015;5:e008737.
- Koskela H. Current and future needs for hospital treatment of pneumonia [Article in Finnish]. *Suomen Lääkärilehti* 2013;68:1349–55.
- Polkowska A, Harjunpää A, Toikkanen S, *et al.* Increased incidence of Mycoplasma pneumoniae infection in Finland, 2010–2011. *Euro Surveill* 2012;17:20072.
- Manderbacka K, Arffman M, Lyytikäinen O, *et al.* What really happened with pneumonia mortality in Finland in 2000–2008?: a cohort study. *Epidemiol Infect* 2013;141:800–4.
- Skull SA, Andrews RM, Byrnes GB, *et al.* ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged ≥ 65 years. *Epidemiol Infect* 2008;136:232–40.
- Schuck-Paim C, Taylor RJ, Simonsen L, *et al.* Challenges to estimating vaccine impact using hospitalization data. *Vaccine* 2017;35:118–24.
- Current care guidelines – pneumonia [Article in Finnish]. The Finnish Medical Society. *Duodecim* 2008;124:2030–9. Available online at: www.kaypahoito.fi.
- Statistics Finland. Official Statistics of Finland (OSF): population projection 2012–2060. http://www.stat.fi/til/vaenn/2012/vaenn_2012-09-28_tie_001_en.html (accessed 20 Feb 2016).